Rahul Bhargava: Late-Breaking ASH 2025 Highlight
Rahul Bhargava, Director and Head of Hematology, Hematoncology and Stem Cell Transplant at Fortis Health Care , shared a post from ASH on LinkedIn:
“Late-Breaking ASH 2025 Highlight
MajesTEC-3: Teclistamab + Daratumumab (Tec-Dara) changing the game in Relapsed/Refractory Multiple Myeloma
One curve says it all — HR 0.17, 83.3% 3-year OS, median not reached!
We are witnessing the dawn of a new era where bispecifics and immune-based combinations are pushing survival boundaries beyond imagination.
The Tec-Dara regimen not only doubles durability compared to DPd/DVd but also offers hope for long-term disease control — a vision once unimaginable in RRMM.
The best part? These cutting-edge therapies are now available at the Fortis Advanced Center for Myeloma and Lymphoma Research — bringing the world’s most advanced science straight to our patients.
Truly unbelievable progress — the future of myeloma treatment is being rewritten.”
More posts on Hemostasis Today.
-
Jan 24, 2026, 15:54Nicolas Nesseler on How Common and Serious is Post-Op Bleeding After Heart Transplantation
-
Jan 24, 2026, 15:43Roey Tagansky on Tu Youyou and the Rediscovery That Defeated Malaria
-
Jan 24, 2026, 15:27Mavis Agnes Kisakye on Community Impact at HFU
-
Jan 24, 2026, 15:15Jo Jewell Announces Novartis Foundation and Novo Nordisk Collaboration
-
Jan 24, 2026, 15:02Todd Davenport on The Impacts of Long COVID
-
Jan 24, 2026, 14:47Seth D Ginsberg: Last Month, Something Meaningful Happened in Tokyo
-
Jan 24, 2026, 14:33Heghine Khachatryan on New Insights Into Bleeding Mechanisms in Acquired Hemophilia A
-
Jan 24, 2026, 14:21Mamta Soni Shares Highlights from CBC Chennai 2026
-
Jan 24, 2026, 13:52Larysa Mykhailova on Characterization of Allogeneic Platelet Gel